Catalyst Pharma Appoints Dr. Curran to Board

Catalyst Pharma ( (CPRX) ) has issued an announcement.

On August 4, 2025, Catalyst Pharmaceuticals announced the appointment of Dr. Daniel J. Curran to its Board of Directors, expanding the board from six to seven members. Dr. Curran brings over 25 years of experience in the pharmaceutical industry, with expertise in strategy, business development, and rare disease therapies. His appointment is expected to bolster Catalyst’s growth strategy, focusing on maximizing its rare disease portfolio and acquiring strategically aligned assets.

The most recent analyst rating on (CPRX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Catalyst Pharma stock, see the CPRX Stock Forecast page.

Spark’s Take on CPRX Stock

According to Spark, TipRanks’ AI Analyst, CPRX is a Outperform.

Catalyst Pharma’s overall stock score reflects its strong financial performance and strategic growth initiatives. While the technical indicators suggest caution, the company’s robust earnings call and corporate events bolster its growth outlook. Valuation remains reasonable, providing a balanced view of potential risks and opportunities.

To see Spark’s full report on CPRX stock, click here.

More about Catalyst Pharma

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on improving the lives of patients with rare diseases. The company specializes in in-licensing, commercializing, and developing innovative therapies, with a strong commitment to patient care and accessibility. Catalyst has a significant presence in the U.S. and is recognized for its growth and success, as evidenced by its inclusion in the Forbes 2025 list of America’s Most Successful Mid-Cap Companies and the 2024 Deloitte Technology Fast 500 list.

Average Trading Volume: 1,266,642

Technical Sentiment Signal: Buy

Current Market Cap: $2.58B

Find detailed analytics on CPRX stock on TipRanks’ Stock Analysis page.